Shots:AstraZeneca to acquire EsoBiotec, which will operate as AstraZeneca’s subsidiary, while maintaining its operations in Belgium to advance cell therapy As per the deal, AstraZeneca will acquire all outstanding equity of EsoBiotec on a cash & debt-free basis for ~$1B, incl. $425M upfront at closing & ~$575M in development & regulatory milestones; closing…